Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Pandemics and Biosecurity
7MAY

WHO upgrades Hondius Andes risk to MODERATE

3 min read
15:24UTC

WHO revised Disease Outbreak News 600 on 9 May, upgrading the ship-level risk for the MV Hondius Andes hantavirus cluster from LOW to MODERATE and confirming all six laboratory-tested cases as Andes virus by PCR and sequencing, with a 38% case-fatality rate across 8 cases and 3 deaths.

ScienceDeveloping
Key takeaway

WHO's MODERATE upgrade on 9 May confirmed Andes virus in all six lab cases, with a 38% case-fatality rate.

WHO revised DON 600 on 9 May, upgrading the ship-level risk for the MV Hondius cluster from LOW to MODERATE and confirming that all six laboratory-tested cases were Andes virus by PCR and full genome sequencing.⁠1 The revision supersedes the original DON 599 assessment, which logged 7 cases, 3 deaths, and applied standard hantavirus droplet precautions rather than the Andes-specific airborne isolation tier. The Swiss case , confirmed days after DON 599 was published, is the event that forced the upgrade: the Andes strain identification changed both the transmission model and the infection-control calculus.

At the point of revision, the WHO case count stood at 8 cases (6 confirmed, 2 probable) and 3 deaths, producing a 38% case-fatality rate. That CFR is consistent with the baseline for Andes hantavirus in laboratory-confirmed cases, which historically runs 30-40%. The six reporting countries at the time of revision were the Netherlands, South Africa, Switzerland, Germany, the United Kingdom, and Spain. A MODERATE ship-level risk assessment indicates that transmission from the MV Hondius environment to passengers is considered plausible, though person-to-person secondary transmission ashore had not been confirmed.

PAHO's December 2025 Epidemiological Alert had already placed Southern Cone health authorities on notice about rising hantavirus case-fatality figures before the voyage , and the pre-voyage birding expedition traversed Oligoryzomys longicaudatus habitat in Chile, Uruguay, and Argentina, according to WHO's Maria Van Kerkhove, establishing the most plausible rodent-exposure window.⁠2 The vessel completed disembarkation at Tenerife on 11 May, closing the primary exposure environment. The MODERATE designation remains in force while contact tracing and 45-day incubation monitoring continue across all six countries.

Deep Analysis

In plain English

Most viruses spread through large droplets, which means a surgical mask and keeping your distance from the patient is enough protection for nurses and doctors. A smaller number of viruses spread through tiny airborne particles that can drift across a room, and those require a different kind of mask (called an N95 or FFP3 respirator) and a room designed to stop air flowing outward. **Andes hantavirus** is the only type of hantavirus known to spread between people, so on 8 May the **US Centers for Disease Control** issued guidance requiring hospitals to treat suspected cases as airborne until proved otherwise. The guidance also had a practical message for doctors: a life-support machine called **ECMO** (which does the work of the heart and lungs for a patient) raises survival to about 80% if started early. US patients suspected of having Andes virus are being sent to a specialist hospital in **Nebraska** that has both the ECMO capacity and the bio-containment rooms needed.

What could happen next?
  • Consequence

    Community hospitals receiving suspected Andes cases will need to transfer them to negative-pressure facilities, creating a transfer-delay risk during which nosocomial exposure can occur if precautions are not escalated at the referring hospital.

  • Precedent

    HAN00528 is the first CDC guidance to require airborne precautions for a hantavirus; it will be cited in future guidance for other hantaviruses with potential person-to-person transmission should new evidence emerge.

First Reported In

Update #2 · B3.13 gets better at humans as testing ends

WHO· 12 May 2026
Read original →
Causes and effects
This Event
WHO upgrades Hondius Andes risk to MODERATE
The LOW-to-MODERATE upgrade is the first formal threshold crossing since the Swiss Andes confirmation, and it triggers more demanding case-management guidance for the six countries now reporting cases.
Different Perspectives
IGWG co-chair Tovar da Silva Nunes
IGWG co-chair Tovar da Silva Nunes
The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.
Fraport
Fraport
The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.
European Centre for Disease Prevention and Control
European Centre for Disease Prevention and Control
ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.
Pan American Health Organization
Pan American Health Organization
PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.
Bangladesh Directorate General of Health Services
Bangladesh Directorate General of Health Services
The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.
Minapharm
Minapharm
The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.